Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

INT J LAB HEMATOL：对286个成熟B细胞肿瘤的整合流式细胞术分析显示，CD13可作为诊断亚型的有用标记

2019-02-01 MedSci MedSci原创

诊断亚型B细胞肿瘤
关注

CD13<span style="font-family:宋体; mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: 宋体;mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Calibri; mso-h

CD13是骨髓相关抗原，其可以由B细胞淋巴瘤的亚群表达; 然而，然而，它与其他B细胞相关抗原的表达意义尚不清楚。

研究人员确定了在诊断时进行流式细胞术分析的286个成熟B细胞肿瘤。对每种病例评估CD13，CD45，CD19，CD20，CD25，CD10，CD38，CD22，CD23，FMC7和κ和λ轻链的表达，并与临床病理学特征相关联分析。

结果显示，CD13表达与淋巴浆细胞淋巴瘤（LPL）（16/26）和FMC7阳性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）（11/30）特异性相关。滤泡性淋巴瘤（FL）病例不表达CD13（0/48）。在所有B细胞肿瘤中，CD13表达与FMC7共表达和κ轻链限制正相关，并且与CD10共表达和λ轻链限制呈负相关。在B细胞肿瘤中，CD13与总生存率或无病生存率之间没有显著的相关性。

与其他成熟B细胞淋巴瘤亚型相比，CD13在LPL和FMC7阳性CLL/SLL中表达更为常见，在FL中则不表达，这可能是诊断亚型的一个有用特征。

原始出处：

Hubert Lau MD Alexandra Nagy MD, PhD. An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928011, encodeId=2ab9192801140, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 09 14:59:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273290, encodeId=e84012e3290de, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317481, encodeId=7d7f131e481af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509970, encodeId=0cc515099e0e8, content=<a href='/topic/show?id=d7716530469' target=_blank style='color:#2F92EE;'>#流式细胞术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65304, encryptionId=d7716530469, topicName=流式细胞术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd410182644, createdName=w984448tii, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-10-09 hyf028

    #CD13#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1928011, encodeId=2ab9192801140, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 09 14:59:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273290, encodeId=e84012e3290de, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317481, encodeId=7d7f131e481af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509970, encodeId=0cc515099e0e8, content=<a href='/topic/show?id=d7716530469' target=_blank style='color:#2F92EE;'>#流式细胞术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65304, encryptionId=d7716530469, topicName=流式细胞术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd410182644, createdName=w984448tii, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 xiaoyeshuang

    #B细胞#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1928011, encodeId=2ab9192801140, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 09 14:59:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273290, encodeId=e84012e3290de, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317481, encodeId=7d7f131e481af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509970, encodeId=0cc515099e0e8, content=<a href='/topic/show?id=d7716530469' target=_blank style='color:#2F92EE;'>#流式细胞术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65304, encryptionId=d7716530469, topicName=流式细胞术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd410182644, createdName=w984448tii, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1928011, encodeId=2ab9192801140, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4263, encryptionId=a6b54263ae, topicName=CD13)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Wed Oct 09 14:59:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273290, encodeId=e84012e3290de, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317481, encodeId=7d7f131e481af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509970, encodeId=0cc515099e0e8, content=<a href='/topic/show?id=d7716530469' target=_blank style='color:#2F92EE;'>#流式细胞术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65304, encryptionId=d7716530469, topicName=流式细胞术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cd410182644, createdName=w984448tii, createdTime=Sun Feb 03 08:59:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2019-02-03 w984448tii

    #流式细胞术#

    0

相关资讯

临床要点：乳酸性酸中毒

乳酸性酸中毒是由于乳酸和氢离子在体液中聚集造成，并且常常与不良 的临床预后相关。乳酸性酸中毒的影响由其本身的严重程度和临床情况决定。当乳酸酸中毒合并低流量状态时，死亡率增加近三倍，并且乳酸越高，预后越差。尽管高乳酸血症常常是由于组织缺氧造成，但是也可以由其他原因导致。病因的控制是唯一有效的治疗方法。然而，由于对其病理生理学特点以及在此状态下引起细胞功能障碍的因素两方面的研究进展，从而导致了新疗法的

Clin Gastroenterol H：诊断肝细胞癌后服用他汀类药物与患者存活情况

由此可见，HCC诊断后服用他汀类药物与HCC患者的死亡率降低有关。

Rhinology：在非过敏性鼻炎中，干冷空气激发是一种可靠的诊断工具

对非过敏性鼻炎（NAR）来说，还没有标准的诊断流程。非特异性鼻过敏反应（NHR）可以通过干冷空气（CDA）激发来进行有效的评估，同时也是NAR的一个必要特性。因此，最近，有研究人员评估了CDA激发在区分NAR患者中的诊断价值。研究人员在13名健康志愿者和15名NAR患者中对CDA激发进行了评估。研究发现，与健康志愿者相比，NAR患者在CDA激发后表现出了显著更大的变化，包括总鼻症状得分（TNSS）

产前超声诊断脊髓纵裂畸形1例

孕妇，20岁。孕1产0，孕22+3周，孕期无服用药物及毒物接触史，因常规胎儿畸形筛查就诊于当地医院怀疑胎儿椎管内占位，遂转诊至我院。产前超声检查：胎儿腰段及骶段椎管增宽，脊柱矢状切面发现腰骶部后方探及强回声团，后伴声影，凸入椎管且脊髓圆锥末端平第2骶椎水平，脊柱横断面似可见两束脊髓回声，胎儿小脑形态正常、后颅窝池及各脑室未见明显异常（图1）。超声提示：脊髓异常改变考虑脊髓纵裂合并脊髓栓系综合征。

练就火眼金睛，教你识别真假危急值

假危急值的出现，有可能误导临床医师的诊断、治疗和预后判断，也可能会对患者健康造成损害，或浪费了医疗资源。

人工智能技术可助高效诊断眼疾

据澳大利亚媒体报道，澳研究人员领导的一个国际科研团队开发出一种新技术，利用人工智能分析普通验光设备生成的视网膜图像，可高效识别糖尿病视网膜病变，准确率达98%。

Baidu
map
Baidu
map
Baidu
map